Tests clazakizumab in adults with kidney failure on dialysis
Tests clazakizumab against placebo in dialysis patients with heart disease or diabetes and inflammation.
Plain-language title generated from the registry record
Registry title: Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
Key facts
- Where
- Birmingham, Bradford, Coventry, Derby, Dorchester, Liverpool, London, Londonderry, Salford, Shrewsbury, Stoke-on-Trent, and Wolverhampton, United KingdomSee the 15 sites
- Phase
- Phase 2/3
Where in United Kingdom
- University Hospitals Birmingham NHS Foundation Trust - Birmingham Heartlands Hospital (BHH)Birmingham, United KingdomNo longer taking part
- Bradford Teaching Hospitals NHS Foundation TrustBradford, United KingdomTaking people
- University Hospital Coventry and WarwickshireCoventry, United KingdomTaking people
- University Hospitals of Derby and Burton NHS Foundation Trust, Royal Derby HospitalDerby, United KingdomTaking people
- Dorset County Hospital NHS Foundation Trust - Dorset County Hospital (DCH)Dorchester, United KingdomNo longer taking part
- Royal Liverpool University HospitalLiverpool, United KingdomTaking people
- Hammersmith Hospital Imperial College Healthcare NHS Trust -Hammersmith Hospital - West London Renal and Transplant CentreLondon, United KingdomTaking people
- King´s College NHS TrustLondon, United KingdomTaking people
- St George's University Hospitals NHS Foundation Trust - St GLondon, United KingdomTaking people
- William Harvey Research Institute ; Barts Health NHS Trust - The Royal London HospitalLondon, United KingdomTaking people
- Altnagelvin Area HospitalLondonderry, United KingdomTaking people
- Northern Care Alliance NHS Foundation Trust - Salford Royal NHS Foundation Trust-Salford Care OrganisationSalford, United KingdomTaking people
- The Shrewsbury and Telford Hospital NHS Trust (SaTH) - Royal Shrewsbury HospitalShrewsbury, United KingdomTaking people
- Royal Stoke University HospitalStoke-on-Trent, United KingdomTaking people
- The Royal Wolverhampton NHS Trust - New Cross HospitalWolverhampton, United KingdomTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- CSL Behring
- Trial code
- NCT05485961EU 2022-500273-14-00
- Record updated
- 21 September 2026
- Original description
This is a two-part, phase 2b and phase 3 combined prospective, interventional, multicenter, randomized, double-blind, placebo-controlled study.Read full original descriptionShow less
A Phase 2b / 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis
This is a two-part, phase 2b and phase 3 combined prospective, interventional, multicenter, randomized, double-blind, placebo-controlled study.
Part 1: Phase 2b is a dose-finding study for CSL300 vs placebo. Part 2: Phase 3 aims to assess the efficacy of CSL300 vs placebo on cardiovascular (CV) outcomes and safety in subjects with systemic inflammation and either atherosclerotic cardiovascular disease (ASCVD) or diabetes with end stage kidney disease (ESKD) undergoing maintenance dialysis.
Inclusion: Male or female at least 18 years of age; A diagnosis of ESKD undergoing maintenance dialysis for at least 12 weeks; Serum hs-CRP ≥ 2.0 mg/L; A diagnosis of diabetes mellitus OR ASCVD.
Exclusion: Concomitant use of systemic immunosuppressant drugs; Part 1 (Phase 2b) excludes subjects with a positive TB or a history of latent TB, whereas Part 2 (Phase 3) excludes active TB but allows inclusion of subjects with a latent TB and at least 4 weeks of prophylactic TB treatment; Any life-threatening disease expected to result in death within 12 months; A history of GI perforation, inflammatory bowel disease (except fully excised. ulcerative colitis), or peptic ulcer disease; Clinically significant active infection or history of opportunistic or invasive fungal infection; Subjects who participated in Part 1 (phase 2b) are not eligible to participate in Part 2 (phase 3); Abnormal LFTs.